ArticleFrontiers in oncology2024

Complete response to disitamab vedotin in HER2-low metastatic endometrial carcinoma: a case report and review of the literature.

Hu Feng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.